In a continuing trend within the pharma industry, Elan has signed a deal for the CRO firm PPD to act as the primary service provider for all its development activities.
Many pharma companies have recently inked deals handing over varying degrees of development responsibility to CROs. Covance in particular has...
Welcome to Scrip
Create an account to read this article
Already a subscriber?